科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

未开盘 09-03 16:08:21

13.120

+0.260

+2.02%

最高13.250	最低12.880	成交量231.01万
今开13.090	昨收12.860	日振幅2.88%
总市值77.93亿	流通市值77.93亿	总股本5.94亿
成交额3,016万	换手率0.39%	流通股本5.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":13.12,"timestamp":1788422901002,"preClose":12.86,"halted":0,"volume":2310100,"delay":0,"changeRate":0.020217729393468102,"floatShares":594000000,"shares":594000000,"eps":-0.177264,"marketStatus":"未开盘","change":0.26,"latestTime":"09-03 16:08:21","open":13.09,"high":13.25,"low":12.88,"amount":30158246,"amplitude":0.028771,"askPrice":13.12,"askSize":8500,"bidPrice":13.01,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.173,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":0,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":12.86,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":1.166551,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"1124447538","title":"港股生物科技股大涨，思路迪医药股份涨超80%，云顶新耀涨超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124447538","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124447538?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:30","pubTimestamp":1787189405,"startTime":"0","endTime":"0","summary":"8月20日，港股$生物(000504)$科技股大涨，$思路迪医药股份(01244)$涨超80%，$云顶新耀(01952)$涨超60%，$康希诺生物(06185)$涨超50%，$艾美疫苗(06660)$涨超45%，$剂泰科技-P(07666)$涨超25%，$科济药业-B(02171)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03069","02171","BK1161","06660","03034","09086","09834","BK1583","VXUS","07266","07568","01244","03455","BK1574","06185","XLK","KCAI","BK1585","03086","BK1147","BK1191","01952","BK4588","02834","VGT","07261","TTTN","07522","07666","BK4585","BK1515","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431074","title":"全球首款实体瘤CAR-T卖99万元，科济药业称销售额在下半年确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431074","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431074?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:08","pubTimestamp":1787126930,"startTime":"0","endTime":"0","summary":"今年6月22日，科济药业（02171.HK）的恺力美作为全球首款治疗实体瘤的CAR-T细胞产品获批国内上市，用于晚期胃癌治疗，但售价高达99万元，究竟会有多少患者愿意买单？随着公司半年报披露，该问题受到投资者关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846256878.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846256878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4022","BK1161","BK1587","02171","BK4230","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660941647","title":"科济药业-B绩后涨近5% 中期收益约为6191.9万元同比增长21.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660941647","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660941647?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:13","pubTimestamp":1787105580,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端科济药业-B（02171）绩后涨近5%，截至发稿，股价上涨4.63%，现报15.38港元，成交额2389.73万港元。8月18日，科济药业-B公布2026年中期业绩，收益约为6191.9万元，同比增长21.5%；经调整净亏损3192.7万元，同比收窄55.53%；母公司拥有人应占亏损6666.3万元，同比收窄11.52%；每股亏损0.13元。公告称，收益增长主要由于赛恺泽®的销量有所增加。经调整净亏损减少主要归因于行政开支减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-19/doc-ininvfsy2765577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02171","BK1161","BK1587","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660163104","title":"港股异动 | 科济药业-B(02171.HK)绩后涨超4% 中期母公司拥有人应占亏损同比收窄11.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660163104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660163104?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:51","pubTimestamp":1787104275,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02171","BK1585","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660931174","title":"科济药业-B(02171)公布中期业绩 母公司拥有人应占亏损6666.3万元 同比收窄11.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660931174","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660931174?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:36","pubTimestamp":1787063792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)公布2026年中期业绩，收益约为6191.9万元，同比增长21.5%;经调整净亏损3192.7万元，同比收窄55.53%;母公司拥有人应占亏损6666.3万元，同比收窄11.52%;每股亏损0.13元。公告称，收益增长主要由于赛恺泽®的销量有所增加。经调整净亏损减少主要归因于行政开支减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1587","BK1585","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107735210","title":"科济药业-B（02171）2026年中期收入增至0.62亿元 净亏损收窄至0.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107735210","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107735210?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:31","pubTimestamp":1787063467,"startTime":"0","endTime":"0","summary":"2026年8月18日，科济药业控股有限公司公布截至2026年6月30日止六个月未经审计的中期业绩。报告期内，公司实现收入0.62亿元，同比增长0.11亿元，主要得益于全人源BCMA自体CAR-T产品“赛愷澤”销量增加。同期毛利录得0.42亿元，较上年同期增加0.13亿元；毛利增长同样源于“赛愷澤”销售规模提升。期间净亏损由上年同期的0.75亿元收窄至0.71亿元，减少0.04亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2658926656","title":"港股异动 | 科济药业-B(02171.HK)再涨超4% 旗下通用型CAR-T接连获批 恺力美纳入百万医疗险","url":"https://stock-news.laohu8.com/highlight/detail?id=2658926656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658926656?lang=zh_cn&edition=full","pubTime":"2026-08-12 13:42","pubTimestamp":1786513321,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02171","BK1161","BK1587","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657982196","title":"港股异动 | 科济药业-B(02171)再涨超4% CT1190B获批用于治疗至少二线标准治疗失败的R/R LBCL患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2657982196","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657982196?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:45","pubTimestamp":1786070759,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B再涨超4%，截至发稿，涨4.03%，报15.48港元，成交额2198.66万港元。消息面上，8月7日，科济药业-B发布公告，CT1190B，一种靶向CD19/CD20的通用型CAR-T细胞产品，已获得国家药监局的IND批准，用于治疗至少二线标准治疗失败的复发/难治性大B细胞淋巴瘤患者。CT1190B是一款靶向CD19/CD20的通用型CAR-T细胞疗法，基于科济药业的 THANK-u Plus平台开发，目前正在开展治疗复发/难治性B细胞非霍奇金淋巴瘤的IIT。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1574","BK1585","BK4588","BK1161","KCAI","02171","VXUS","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657664400","title":"科济药业-B(02171)：CT1190B获得国家药监局的IND批准用于治疗至少二线标准治疗失败的复发/难治性大B细胞淋巴瘤(R/R LBCL)患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2657664400","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657664400?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:09","pubTimestamp":1786061373,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布公告，CT1190B，一种靶向CD19/CD20的通用型 CAR-T细胞产品，已获得国家药监局的IND批准，用于治疗至少二线标准治疗失败的复发/难治性大B细胞淋巴瘤(R/R LBCL)患者。CT1190B的IIT研究结果已在2026年欧洲血液学协会年会上进行壁报展示。CT1190B是一款靶向CD19/CD20的通用型CAR-T细胞疗法，基于科济药业的 THANK-u Plus®平台开发，目前正在开展治疗复发/难治性B细胞非霍奇金淋巴瘤的IIT。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","IND","02171","BK1585","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644076","title":"科济药业-B(02171.HK)：CT1190B获得国家药监局的IND批准用于治疗至少二线标准治疗失败的复发/难治性大B细胞淋巴瘤(R/R LBCL)患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644076?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:09","pubTimestamp":1786061373,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02171","BK1161","BK1585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118940273","title":"科济药业-B：CT1190b获NMPA临床试验许可，针对复发/难治性大B细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1118940273","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118940273?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:05","pubTimestamp":1786061145,"startTime":"0","endTime":"0","summary":"科济药业-B（CARsgen Therapeutics）宣布，其候选药物CT1190b已获得中国国家药品监督管理局（NMPA）的临床试验（IND）许可。该药物将用于治疗复发或难治性大B细胞淋巴瘤（R/R LBCL）患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1161","BK1587","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134436501","title":"科济药业-B发布7月股份变动月报，总股本减少逾826万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1134436501","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134436501?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:51","pubTimestamp":1786017111,"startTime":"0","endTime":"0","summary":"科济药业控股有限公司于2026年8月6日披露2026年7月股份变动月报表。报告显示，截至2026年7月31日，公司授权股本未发生变化，仍为200,000,000,000股，面值每股USD 0.00000025，注册股本总额50,000美元。报告期内，公司已发行股份由上月底的594,675,998股减少至594,229,547股，同时库存股份由7,818,000股减少至0股，总股本相应从602,493,998股降至594,229,547股，减少8,264,451股。上述月报由科济药业-B执行董事李宗海签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142837839","title":"科济药业-B将于2026年8月18日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1142837839","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142837839?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:36","pubTimestamp":1786008990,"startTime":"0","endTime":"0","summary":"科济药业控股有限公司（02171）今日公告，董事会已排定于2026年8月18日（星期二）召开会议。董事会将于当日审议并通过本集团截至2026年6月30日止六个月的中期业绩，并处理其他事项。\n公告同时列明，公司董事会目前由3名执行董事、2名非执行董事及3名独立非执行董事组成。\n公司表示，后续有关2026年中期业绩的详细信息及相关决议，将按香港联交所规定及时披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657688968","title":"港股异动 | 科济药业-B(02171.HK)再涨近4% 通用型BCMA CAR-T产品CT0596国内获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2657688968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657688968?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:07","pubTimestamp":1786000065,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1585","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589898","title":"港股异动丨科济药业-B(02171.HK)涨超4% CT0596已获得国家药监局的IND批准用于治疗R/R MM患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589898","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656589898?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:30","pubTimestamp":1785810652,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02171","BK1161","BK1585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588739","title":"科济药业-B(02171)：CT0596已获得国家药监局的IND批准用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656588739?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:11","pubTimestamp":1785802294,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 发布公告，CT0596，一种靶向BCMA的通用型CAR-T细胞产品，已获得国家药品监督管理局的IND批准，用于治疗复发/难治的多发性骨髓瘤患者。CT0596的IIT研究结果已在2026年欧洲血液学协会年会上进行壁报展示。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus平台开发，目前正在R/R MM或浆细胞白血病中开展IIT进行评估。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1585","BK1587","BK1574","BK1161","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192006097","title":"科济药业-B（02171）通用型CAR-T疗法CT0596获批开展R/R多发性骨髓瘤临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1192006097","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192006097?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:06","pubTimestamp":1785801969,"startTime":"0","endTime":"0","summary":"2026年8月4日，科济药业控股有限公司公告，其自主研发的靶向BCMA通用型CAR-T细胞产品CT0596已获得国家药品监督管理局的临床试验申请批准，用于治疗复发╱难治的多发性骨髓瘤患者。科济药业为一家专注创新CAR-T细胞疗法的生物制药企业，已构建涵盖靶点发现、临床前研究、临床开发及商业化生产的端到端能力。公司强调，无法确保CT0596最终能够成功开发或商业化，提醒投资者在买卖公司股票时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120879985","title":"科济药业-B旗下CT0596获中国药监局临床试验许可，针对复发/难治性多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1120879985","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120879985?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:01","pubTimestamp":1785801692,"startTime":"0","endTime":"0","summary":"科济药业-B（CARSGEN-B）宣布，其创新药物CT0596已获得中国国家药品监督管理局（NMPA）的临床试验默示许可。该药物旨在针对复发/难治性多发性骨髓瘤这一棘手疾病展开治疗探索。这一里程碑式的进展，意味着科济药业在攻克血液肿瘤领域的征程上，又迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1585","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146432966","title":"科济药业-B于7月17日回购322,500股股份，总额约498.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146432966","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146432966?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:42","pubTimestamp":1784299332,"startTime":"0","endTime":"0","summary":"2026年7月17日，科济药业-B发布翌日报表公告，披露其在香港联交所场内回购股份并进行已发行股份变动。根据公告，科济药业-B于2026年7月17日回购322,500股普通股，约占此前已发行股份总数的0.054%。此次回购每股价格区间介于15.28港元至15.68港元，合计耗资约498.12万港元，相关回购股份拟予以注销。本次发行后，公司于2026年7月17日的已发行股份数为594,228,998股，库存股份则保持在7,228,000股，合计达601,456,998股。公司于2026年5月22日获得回购授权，获准回购最多57,096,024股股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科济药业-B于7月17日回购322,500股股份，总额约498.12万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652289463","title":"科济药业-B(02171)7月17日斥资498.12万港元回购32.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652289463","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652289463?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:38","pubTimestamp":1784299082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布公告，于2026年7月17日斥资498.12万港元回购32.25万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1585","02171","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.0423},{"period":"1month","weight":-0.0135},{"period":"3month","weight":-0.1961},{"period":"6month","weight":0.207},{"period":"1year","weight":-0.4095},{"period":"ytd","weight":-0.1165}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司。该公司的主营业务是从事开发嵌合抗原受体T细胞（CAR-T）细胞疗法，以满足临床需求，包括但不限于血液恶性肿瘤、实体瘤及自身免疫性疾病。该公司的主要产品包括赛恺泽（泽沃基奥仑赛注射液）、舒瑞基奥仑赛注射液、通用型CAR-T细胞产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.035849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.015777},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.022715},{"month":8,"riseRate":0.5,"avgChangeRate":0.052678},{"month":9,"riseRate":0.333333,"avgChangeRate":0.026766},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}